DiaSorin (OTCMKTS:DSRLF) Shares Gap Up – Still a Buy?

DiaSorin S.p.A. (OTCMKTS:DSRLF)’s stock price gapped up before the market opened on Wednesday . The stock had previously closed at $67.00, but opened at $80.35. DiaSorin shares last traded at $80.35, with a volume of 100 shares.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on DSRLF shares. Zacks Research upgraded shares of DiaSorin to a “hold” rating in a research report on Tuesday, May 12th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of DiaSorin in a report on Tuesday, February 10th. Finally, UBS Group lowered shares of DiaSorin from a “buy” rating to a “neutral” rating in a research note on Thursday, April 9th. Two analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold”.

DiaSorin Price Performance

The stock’s 50 day simple moving average is $68.57 and its 200-day simple moving average is $74.41.

About DiaSorin

DiaSorin S.p.A. is an Italy?based global biotechnology company specializing in the development, manufacture and marketing of in vitro diagnostic products. Headquartered in Saluggia, DiaSorin serves clinical laboratories, hospitals and physician offices with a broad portfolio of immunodiagnostic assays and molecular diagnostic tests. The company’s shares trade on the Milan Stock Exchange and are available in the United States as over?the?counter (OTC) securities under the symbol DSRLF.

At the core of DiaSorin’s business are immunodiagnostic systems that measure antibodies, antigens and hormones in human samples.